Revlimid (Lenalidomide) for Lymphoma | MyLymphomaTeam

Connect with others who understand.

sign up Log in
About MyLymphomaTeam
Powered By

Revlimid is a prescription medication approved by the U.S. Food and Drug Administration (FDA) to treat mantle cell lymphoma and multiple myeloma. Revlimid is often combined with other drugs such as a corticosteroid or Velcade (bortezomib). Revlimid is also known by its drug name, lenalidomide.

Revlimid is an immunomodulator – a drug that modulates the immune system. Revlimid is believed to work by preventing cellular proliferation, inducing cellular death, and upregulating the immune system.

How do I take it?
Revlimid is taken orally on specific days in a 28-day cycle.

Revlimid comes in the form of a capsule.

Side effects
The FDA-approved label for Revlimid lists common side effects including insomnia, dizziness, fever, fatigue, cough, rash, weakness, cold or flu symptoms, bronchitis, trouble breathing, back pain, muscle cramps, tremors, nausea, diarrhea, constipation, abdominal pain, low white blood cell counts, and swelling in the extremities.

Rare but serious side effects listed for Revlimid include severe fetal harm in pregnant women, liver failure, severe skin reactions, and increased risk for heart attack, stroke, dangerous blood clots, and other types of cancer.

Individuals diagnosed with chronic lymphocytic leukemia (CLL) should not take Revlimid due to increased risk for severe and fatal cardiac side effects.

For more details about this treatment, visit:

Revlimid — Celgene

Immunotherapy for Non-Hodgkin Lymphoma — American Cancer Society

Drug Therapy for Multiple Myeloma — American Cancer Society

Continue with Facebook
Continue with Google
Lock Icon Your privacy is our priority. By continuing, you accept our Terms of use, and our Health Data and Privacy policies.
Already a Member? Log in